News and Stories About targeted therapy
Meet Our 2018 Research Grantees: Translational Awards
This year, the Pancreatic Cancer Action Network (PanCAN) awarded nine prestigious research grants to scientists and clinicians in the United […]
READ MORE
Survivor Advocates for a Second Opinion
In June 2014, David Wingo went to his doctor about abdominal pain. While investigating the pain, his doctor noticed a […]
READ MORE
Clinical Trial Participant Encourages Patients to Actively Seek Clinical Trials
In September 2015, Earl Groce returned home to North Carolina after driving 5,500 miles cross-country for his first trip to […]
READ MORE
PanCAN’s Precision Medicine Results Featured at Major Meeting
The 2018 Gastrointestinal (GI) Cancers Symposium is taking place in San Francisco, Jan. 18 to 20. The meeting brings together […]
READ MORE
2017 Year in Review: Top 10 News Stories
Editor’s note: This article is another installment in our “Year in Review” series recapping the year’s top stories in pancreatic […]
READ MORE
2017 Year in Review: Progress in Research, Part 1
Editor’s note: This article is the first in our “Year in Review” series recapping the year’s top stories in pancreatic […]
READ MORE
Discovery of Rare Mutation Gives Survivor Options, Hope
Akshay Mehta, MD, was in the middle of performing an orthopedic surgery when his first pancreatic cancer symptom arose. “I […]
READ MORE
5 Things to Know about BRCA Mutations and Pancreatic Cancer
Did you know that mutations in the “breast cancer genes,” BRCA1 and BRCA2, increase a person’s lifetime risk of developing […]
READ MORE
Forbes Article Discusses Potential of PARP Inhibitors to Treat Certain Pancreatic Cancer Patients
The so-called breast cancer genes BRCA1 and BRCA2 were originally found to increase a woman’s risk of breast cancer when […]
READ MORE
Studying How a New Immunotherapy Works in Each Patient
Thanks to the generosity of donors, we awarded our largest-ever grant of $2 million in 2016 to accelerate a large-scale […]
READ MORE
Critical Clues Toward Targeting KRAS Mutations
Two new research studies offer encouraging steps toward developing effective therapies to target the notoriously challenging RAS mutations. About 95 […]
READ MORE
